AbCellera vs Advanced Microbubbles
Side-by-side comparison of AI visibility scores, market position, and capabilities
Vancouver-based antibody discovery platform with 104+ partner programs; $75M FY2025 revenue. Expanding into wholly owned assets with ABCL635 in Phase 1 for vasomotor symptoms.
About
AbCellera Biologics was founded in 2012 in Vancouver, Canada by Carl Hansen, growing out of research at the University of British Columbia. The company built a high-throughput antibody discovery platform integrating microfluidics, genomics, single-cell sequencing, and AI/ML to rapidly identify therapeutic antibody candidates from natural immune responses. AbCellera played a prominent role in the COVID-19 pandemic by discovering bamlanivimab for Eli Lilly in under 90 days.\n\nAbCellera's partnership model operates on a discovery fee plus downstream milestone and royalty structure, having started over 104 partner-initiated programs with downstream participation as of December 2025. Partners include major pharmaceutical companies and biotechs; the company expanded its collaboration with AbbVie in 2025 to develop T-cell engagers for oncology. Total FY2025 revenue was $75 million ($47M from royalties/licensing, $27M from partnered program work), compared to $29 million in 2024—a dramatic increase driven by royalty flows from approved medicines.\n\nIn 2025 AbCellera began transitioning from pure partnership model toward wholly owned therapeutic assets, with ABCL635 (a GnRH receptor antibody for vasomotor symptoms) entering Phase 1. The company maintains approximately $700 million in liquidity, providing a long runway. AbCellera is considered a foundational infrastructure provider for the antibody-based drug discovery ecosystem.
Advanced Microbubbles develops ultrasound-activated microbubble technology for targeted drug and gene delivery, with a primary focus on oncology; microbubbles encapsulate therapeutic agents and release them precisely at tumor sites via focused.
About
Advanced Microbubbles Inc. is a biomedical technology company developing ultrasound-triggered microbubble platforms for targeted drug and gene delivery, with a primary therapeutic focus on cancer treatment. The company's core technology involves engineering microscopic gas-filled bubbles that can be loaded with chemotherapy drugs, gene therapy vectors, or other therapeutic payloads. When these microbubbles circulate through the bloodstream and reach the target tissue (such as a tumor), focused ultrasound is applied externally to cause the bubbles to oscillate and rupture — releasing the therapeutic payload precisely at the intended site with minimal systemic exposure.
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.